Antipsychotic Drug Treatment in First-Episode Psychosis. Should Patients be Switched to a Different Antipsychotic Drug After 2, 4, or 6 Weeks of Nonresponse?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F10%3A10023910" target="_blank" >RIV/00216208:11150/10:10023910 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00179906:_____/10:10023910

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Antipsychotic Drug Treatment in First-Episode Psychosis. Should Patients be Switched to a Different Antipsychotic Drug After 2, 4, or 6 Weeks of Nonresponse?

Popis výsledku v původním jazyce

The objective of the study was to test whether patients should be switched to an alternative antipsychotic treatment at 2, 4, or 6 weeks from treatment initiation. Remission within 12 months was assessed in 299 first-episode patients who completed the full 12-month European First-Episode Schizophrenia Trial. Based on baseline and 2-week assessments, remission status was correctly predicted in 61% of the patients. This percentage increased to 63% and 68% by the inclusion of 4- and 6-week assessments, respectively. Although we confirmed earlier findings that 2-week measures of response are associated with remission, the prediction of remission is significantly improved by the inclusion of 4- and 6-week assessments.

Název v anglickém jazyce

Antipsychotic Drug Treatment in First-Episode Psychosis. Should Patients be Switched to a Different Antipsychotic Drug After 2, 4, or 6 Weeks of Nonresponse?

Popis výsledku anglicky

The objective of the study was to test whether patients should be switched to an alternative antipsychotic treatment at 2, 4, or 6 weeks from treatment initiation. Remission within 12 months was assessed in 299 first-episode patients who completed the full 12-month European First-Episode Schizophrenia Trial. Based on baseline and 2-week assessments, remission status was correctly predicted in 61% of the patients. This percentage increased to 63% and 68% by the inclusion of 4- and 6-week assessments, respectively. Although we confirmed earlier findings that 2-week measures of response are associated with remission, the prediction of remission is significantly improved by the inclusion of 4- and 6-week assessments.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FL - Psychiatrie, sexuologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Clinical Psychopharmacology

ISSN

0271-0749

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

—

Kód UT WoS článku

000275722300011

EID výsledku v databázi Scopus

—